openPR Logo
Press release

Abeona Therapeutics Inc. (NASDAQ: ABEO) Investor Alert: Deadline in Lawsuit on January 2, 2020

12-27-2019 10:41 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on January 2, 2020 in the lawsuit for certain investors in Abeona Therapeutics Inc. (NASDAQ: ABEO).

A Deadline is coming up on January 2, 2020 in the lawsuit for certain investors in Abeona Therapeutics Inc. (NASDAQ: ABEO).

A deadline is coming up on January 2, 2020 in the lawsuit filed for certain investors of Abeona Therapeutics Inc. (NASDAQ: ABEO) over alleged securities laws violations by Abeona Therapeutics Inc.

Investors who purchased shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) have certain options and there are strict and short deadlines running. Deadline: January 2, 2020. NASDAQ: ABEO stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of purchasers of Abeona Therapeutics Inc. (NASDAQ: ABEO) common shares between May 31, 2018 and September 23, 2019, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that between May 31, 2018 and September 23, 2019, the defendants made false and/or misleading statements and/or failed to disclose that Abeona’s Chemical, Manufacturing and Controls (“CMC”) and internal controls and procedures and/or compliance policies were inadequate, that as a result, the Company failed to provide sufficient data points on the transport stability of EB-101 to clinical sites, or else such transport stability was insufficient, that consequently, it was foreseeable that the U.S. Food and Drug Administration (“FDA”) would reject approval for the start of the VITAL Study until such issues were addressed, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.

Those who purchased shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Abeona Therapeutics Inc. (NASDAQ: ABEO) Investor Alert: Deadline in Lawsuit on January 2, 2020 here

News-ID: 1886788 • Views: 274

More Releases from Shareholders Foundation

Lawsuit filed for Investors in shares of Green Dot Corporation (NYSE: GDOT)
An investor, who purchased shares of Green Dot Corporation (NYSE: GDOT), filed a lawsuit over alleged Securities Laws violations by Green Dot Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Green Dot Corporation (NYSE: GDOT) have certain options and for certain investors are short and strict deadlines running. Deadline: February 17, 2020. NYSE: GDOT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or
Investigation for Long-Term Investors in shares of Nektar Therapeutics (NASDAQ: …
An investigation was annpounced concerning potential breaches of fiduciary duties by certain directors and officers of Nektar Therapeutics. Investors who are current long term investors in Nektar Therapeutics (NASDAQ: NKTR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: NKTR stocks follows a lawsuit filed against Nektar Therapeutics over
Deadline coming up on Jan. 20th in Lawsuit filed for Investors in shares of Cano …
A deadline is coming up on January 20, 2020 in the lawsuit filed for certain investors of Canopy Growth Corporation (NYSE: CGC) over alleged securities laws violations by Canopy Growth Corporation. Investors who purchased shares of Canopy Growth Corporation (NYSE: CGC) have certain options and there are strict and short deadlines running. Deadline: January 20, 2020. NYSE: CGC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation for Investors in NYSE: LTHM shares announced over potential Securi …
Livent Corporation is under investigation concerning potential securities laws in connection with certain financial statements. Investors who purchased shares of Livent Corporation (NYSE: LTHM), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Livent Corporation (NYSE: LTHM) concerning whether a series of statements by Livent Corporation

All 5 Releases


More Releases for Abeona

Epidermolysis Bullosa (EB) Therapeutics- Pipeline Analysis 2018 | Abeona Therape …
Epidermolysis bullosa (EB), is a rare genetic connective tissue skin disorder that causes blisters and allows skin to become fragile. Blisters and areas of skin loss (erosions) occur in response to minor injury or friction, such as rubbing or scratching. The disease affects 1 out of every 20,000 births in the U.S. Download the sample report @ https://www.pharmaproff.com/request-sample/1130 The symptoms of epidermolysis bullosa are redness and heat around an open area
Fanconi’s Anemia Therapeutics- Pipeline Analysis 2018, Clinical Trials & Resul …
Fanconi anemia is an inherited disease, caused by mutations in FA genes. These genes provide instructions to repair certain types of DNA damage in the human body. The cells of healthy people often repair DNA damage; however, cells affected by Fanconi anemia are not able to repair damages. Download the sample report at: https://www.pharmaproff.com/request-sample/1038 The symptoms associated with the disease are decreased blood cell counts, bone problems, vitiligo, deafness, eye problems,
Batten Disease- Pipeline Including Key Players- Abeona Therapeutics, Amicus Ther …
A new research document is added in HTF MI database of 76 pages, titled as 'Batten Disease - Pipeline Review, H1 2019' with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like North America, South America, Asia, Europe & Others and important players/vendors such as Abeona Therapeutics Inc, Amicus Therapeutics Inc, Exicure Inc, Recursion Pharmaceuticals Inc, RegenxBio Inc, Spark Therapeutics Inc The report
Global Fanconi Anemia Drug Market 2018 - Abeona Therapeutics Inc, Genethon SA
Apex Market Reports, recently published a detailed market research study focused on the “Fanconi Anemia Drug Market” across the global, regional and country level. The report provides 360° analysis of “Fanconi Anemia Drug Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Fanconi
Polymer Drug Conjugates Market 2017 -3S Bio, Abeona Therapeutics, Abramson Cance …
Apex Research, recently published a detailed market research study focused on the "Polymer Drug Conjugates Market" across the global, regional and country level. The report provides 360° analysis of "Polymer Drug Conjugates Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Polymer Drug Conjugates industry, and estimates the future trend of
Polymer Drug Conjugates Market Size 2017 3S Bio, Abeona Therapeutics, Allied, As …
Polymer Drug Conjugates Market Research Report A market study ” Global Polymer Drug Conjugates Market ” examines the performance of the Polymer Drug Conjugates market Size 2017. It encloses an in-depth Research of the Polymer Drug Conjugates market state and the competitive landscape globally. This report analyzes the potential of Polymer Drug Conjugates market in the present and the future prospects from various angles in detail. The Global Polymer Drug Conjugates